Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $8.5652W HIGH $14.76
Volume
6.89 K
Value Traded
9.55 K
Short % Float
0.08%
-1.27%Week
-3.36%1 Month
-0.43%3 Month
+10.78%6 Month
+21.91%5 Year
-16.84%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
60.95 M
EPS (TTM)
-1.23
P/E Ratio
-
Ent. Value
5.09 M
Total Shares
5.83 M
Float Shares
2.97 M
Insiders
49.20%
Institutions
7.23%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
DXR Catalyst Timeline
Dated clinical, regulatory and corporate events for Daxor Corporation
Past FDA Catalysts and PDUFA Decisions
How DXR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Daxor Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every DXR program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Feldschuh Michael RichardDirector, Officer (Chief Executive Officer) | Buy | 1,000 213,694 held | $9.07 | 04/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DXR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DXR for Q2 2026. | ||||
DXR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DXR ranks across every disease it competes in
Competitive Position is a premium feature
See how DXR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDXR News
DXRDaxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Daxor Corporation will showcase its next-generation Blood Volume Analyzer (BVA) at the HFSA Annual Scientific Meeting in Phoenix, AZ, from October 9-12, 2026. The BVA is FDA-cleared and offers rapid results while using less blood, enhancing heart failure management. Clinical evidence presented at the event will highlight its effectiveness in complex cases.
Read more →DXRDaxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor
Daxor Corporation has received a U.S. patent for its innovative Remote Blood Volume Monitor, which allows for continuous, remote tracking of blood volume using wearable sensors. This technology aims to improve patient care for chronic conditions such as heart failure by providing real-time updates and predictive alerts. The system integrates with existing monitoring technologies to enhance clinical decision-making.
Read more →DXR▲ +5.4%on this news
Daxor Leverages MedAxiom CV Transforum Spring’26 to Accelerate Commercial Adoption of Blood Volume Analysis
Daxor Corporation will showcase its Blood Volume Analyzer technology at the MedAxiom CV Transforum Spring'26 Conference. This event aims to connect Daxor with key decision-makers in cardiovascular care, emphasizing the economic benefits of their technology. Studies indicate that BVA-guided care can significantly improve patient outcomes, including reduced mortality and hospital stays.
Read more →DXRDaxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center
Daxor Corporation has launched a new Blood Volume Analysis (BVA) program at a leading cardiology center in Southwest Ohio. This initiative aims to enhance chronic disease management by providing rapid blood volume metrics without the need for onsite labs. The program is expected to improve patient outcomes and streamline clinical decision-making in heart failure care.
Read more →DXRDaxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026
Daxor Corporation presented new clinical data at the SCCM 2026 Congress, validating its Blood Volume Analyzer (BVA) as a superior tool for detecting capillary leak compared to traditional clinical scores. The study highlighted the BVA's ability to measure albumin escape rates directly, addressing a critical gap in diagnosing conditions like heart failure. This positions Daxor as a leader in providing precise blood volume measurement technology.
Read more →DXRDaxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions
Oak Ridge, TN, March 17, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans,
Read more →DXRDaxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress
Advancing Precision Fluid Management in the ICU to Reduce Mortality and Hospital Length of Stay Oak Ridge, TN, March 10, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will showcase its new,
Read more →DXRDaxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026
Daxor Corporation will participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference on March 10-11, 2026. CEO Michael Feldschuh is scheduled to present on March 10 and will hold one-on-one meetings with investors on March 11. The conference aims to enhance investor engagement and showcase Daxor's innovative blood volume measurement solutions.
Read more →DXRDaxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Daxor Corporation's CEO Michael Feldschuh provided a corporate update highlighting a transformative year in 2025, marked by a 45% increase in revenues and FDA clearance for a new Blood Volume Analyzer. The company reported a net asset increase and successfully raised $9 million to support growth. However, it also faced operational losses due to significant R&D investments.
Read more →DXRDaxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
Daxor Corporation reported significant growth for the fiscal year 2025, with a 45% increase in operating revenue and a rise in net asset value to $9.07 per share. The company received FDA 510(k) clearance for its next-generation Blood Volume Analyzer, enhancing its product offerings. Despite an operating loss, Daxor's strategic realignment and capital investments position it for future growth.
Read more →DXRDaxor Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee
Daxor Corporation is expanding its outpatient presence by launching a new BVA diagnostic program in Southern Middle Tennessee. This program utilizes the ezBVA Lab to provide accurate blood volume measurements, enhancing clinical decision-making in cardiology. The initiative aims to improve patient outcomes and reduce healthcare costs without requiring capital investment.
Read more →DXRDaxor Corporation Announces Transition To Securities Exchange Act of 1934 Reporting Company, Reaffirming Focus on Core Blood Volume Analysis and Diagnostic Business
Daxor Corporation announced its transition to the Securities Exchange Act of 1934, moving away from the Investment Company Act of 1940. This strategic shift aims to align its regulatory framework with its growth as a medical diagnostic company. The company continues to focus on its FDA-cleared Blood Volume Analysis technology, which enhances patient care. Completion of the transition is expected by the end of Q2 2026, pending regulatory approvals.
Read more →DXR▼ -8.1%on this news
Daxor Corporation Announces $9 Million Registered Direct Offering
Daxor Corporation has announced a $9 million registered direct offering of 765,958 shares at $11.75 each. The offering is set to close on January 26, 2026, and aims to fund general corporate purposes. Lake Street Capital Markets is the exclusive placement agent for this transaction. The company focuses on improving healthcare through its patented Blood Volume Analysis technology.
Read more →DXRDaxor Fuels Growth with Three New Facility Adoptions and Deployment of Next-Generation BVA Analyzer
Daxor Corporation has announced the expansion of its Blood Volume Analysis platform into three new facilities, showcasing increasing market traction. The company is implementing a dual-solution strategy with on-site analyzers and the ezBVA Lab Service, which is expected to drive sales growth. This initiative aims to improve patient outcomes and enhance fluid management in various healthcare settings.
Read more →DXRDaxor CEO Michael Feldschuh to Engage Investors at Exclusive Maxim Growth Summit
Daxor Corporation's CEO, Michael Feldschuh, will participate in the Maxim Growth Summit on October 22-23, 2025, in New York City. The summit will host a select group of 40 healthcare companies and features notable speakers. Feldschuh will hold one-on-one meetings with institutional investors to discuss Daxor's innovative blood volume measurement technology.
Read more →DXRDaxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
Daxor Corporation will showcase its new BVA diagnostic technology at the MedAxiom CV Transforum Fall '25 Conference in Austin, TX. CEO Michael Feldschuh expressed optimism that this launch will boost sales and market presence. The technology aims to improve patient outcomes by addressing issues like hospital readmissions. Daxor's 50 years of experience positions it well for market expansion.
Read more →DXR▲ +6.2%on this news
Daxor Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA
Daxor Corporation has announced the FDA clearance of its next-generation BVA analyzer, which promises to enhance fluid management in heart failure patients. At the HFSA Annual Scientific Meeting, clinical data revealed that BVA-guided care significantly reduces hospital readmissions and improves survival rates. The company is well-positioned to capture a substantial share of the multi-billion-dollar healthcare market.
Read more →DXRDaxor Corporation Unveils Breakthrough Next-Gen BVA Analyzer at HFSA Annual Scientific Meeting
Daxor Corporation will showcase its new FDA-cleared blood volume analyzer at the HFSA Annual Scientific Meeting. This next-generation device promises to enhance fluid management in heart failure patients, being three times faster and requiring 50% less blood than its predecessor. The company aims to set a new standard of care with this innovative technology.
Read more →DXR▲ +6.6%on this news
Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care
Daxor Corporation's recent pilot study published in the Journal of Critical Care highlights the inaccuracies in clinical assessments of fluid status in critically ill patients. The study demonstrates the effectiveness of Daxor's Blood Volume Analysis (BVA) technology in accurately measuring blood volume, which is crucial for managing conditions like sepsis and COVID-19. The findings underscore the importance of precise diagnostics in critical care settings and the potential for improved patient outcomes.
Read more →About Daxor Corporation
Headquarters350 FIFTH AVENUE, NEW YORK, NY, 10118
BIOPHARMAWATCH ELITE PLUS
Trade the next DXR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime